US EditionPublished • loading... • Updated
Amgen Is Quietly Crushing the Dow and Nobody Is Talking About It
Summary by Trading Tips
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Amgen Is Quietly Crushing the Dow and Nobody Is Talking About It
While everyone obsesses over Nvidia’s latest earnings and the AI selloff carnage, Amgen has been on a tear that would make most tech stocks jealous. The biotech giant is up 17% year-to-date, outperforming the Dow’s measly 2.3% return by a factor of seven. And the best part? The story is just getting started. Amgen’s Q4 earnings in early February set the tone. Revenue came in at $9.9 billion with adjusted EPS of $5.29 — both beating estimates. Ma…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
